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ABSTRACT	  










	  Renal	   chronic	   transplant	   dysfunction	   (CTD)	   is	   the	   leading	   cause	   of	   long-­‐term	   loss	   of	  transplanted	   kidneys	   (1,2).	   CTD	   is	   the	   result	   of	   tissue	   remodeling	   in	   the	   intrarenal	  arteries,	   glomeruli	   and	   tubulointerstitium	   leading	   to	   transplant	   vasculopathy,	   focal	  glomerulosclerosis	   (FGS),	   interstitial	   fibrosis	   and	   tubular	   atrophy	   (2-­‐4).	  These	   lesions	  are	  characterized	  by	  accumulation	  of	  extracellular	  matrix,	  activation	  of	  mesangial	  cells,	  interstitial	   myofibroblasts	   and	   tubular	   epithelial	   cells,	   and	   chronic	   inflammation.	   To	  date,	   due	   to	   the	   lack	   of	   knowledge	   on	   the	   pathogenetic	   mechanisms	   leading	   to	   the	  development	   of	   these	   lesions,	   no	   effective	   therapies	   are	   available	   to	   prevent	   or	   treat	  renal	   CTD.	   Progressive	   loss	   can	   only	   be	   retarded	   by	   anti-­‐hypertensive	   and	   anti-­‐proteinuric	  treatment	  in	  combination	  with	  lipid	  lowering	  drugs.	  Recently,	   we	   showed	   accumulation	   of	   the	   heparan	   sulfate	   proteoglycans	   (HSPGs)	  collagen	   type	  XVIII	  and	  perlecan	  during	  glomerular	  and	  vascular	   tissue	  remodeling	   in	  CTD	   in	   rats	   (5).	   However,	   whether	   and	   how	   these	   proteoglycans	   mediate	   tissue	  remodeling	   in	   CTD	   is	   as	   yet	   unknown.	   In	   native	   kidney	   diseases	   and	   ischemia-­‐reperfusion	  injury	  we	  have	  already	  shown	  that	  HSPGs	  are	  involved	  in	  leukocyte	  influx	  and	  proteinuria-­‐mediated	   renal	   injury	   (6-­‐8).	   Perlecan	   is	   a	   large,	  modular,	   pericellular	  HSPG	   with	   a	   spatial	   distribution	   that	   enables	   the	   control	   over	   major	   cell	   signaling	  events,	  such	  as	  migration,	  proliferation	  and	  differentiation	  in	  response	  to	  bound	  growth	  factors.	  It	  is	  composed	  of	  five	  different	  domains,	  of	  which	  the	  C-­‐terminal	  domain,	  named	  endorepellin,	  is	  best	  known	  for	  its	  anti-­‐angiogenic	  properties	  (9,10).	  	  The	  carbohydrate	  side	  chains	  (i.e.	  the	  glycosaminoglycans)	  are	  attached	  to	  proteoglycan	  core	   proteins	   and	   can	   bind	   a	   variety	   of	   ligands	   depending	   on	   their	   highly	   variable	  composition,	   mainly	   variations	   in	   N-­‐	   and	   O-­‐sulfation	   patterns	   (11).	   Along	   with	  chondroitin	  sulfate-­‐	  and	  dermatan	  sulfate	  proteoglycans,	  HSPGs	  form	  the	  large	  majority	  of	   the	   proteoglycan	   family.	   Potential	   ligands	   are	   chemokines	   (11)	   and	   growth	   factors	  such	   as	   basic	   fibroblast	   growth	   factor	   (bFGF/FGF2)	   (12,13).	   Proteoglycans	   are	   highly	  involved	  in	  morphogenesis	  and	  tissue	  remodeling	  processes	  (14-­‐19).	  Studies	   in	   non-­‐transplantation	   models	   of	   renal	   and	   vascular	   disease	   have	   shown	  potential	   roles	  of	  FGF2	   in	  FGS	  and	  neointima	   formation	   (20-­‐23).	  These	  data	   led	  us	   to	  hypothesize	  that	  interaction	  of	  FGF2	  with	  proteoglycans	  also	  affects	  tissue	  remodeling	  processes	  in	  CTD.	  To	  test	  this	  hypothesis	  we	  used	  an	  experimental	  rat	  CTD	  model,	  from	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which	   we	   microdissected	   glomeruli,	   the	   arterial	   media	   as	   well	   as	   the	   neointima	  followed	  by	  low	  density	  qRT-­‐PCR	  analysis	  for	  matrix	  and	  cell	  surface	  proteoglycans	  and	  FGF2.	   In	   addition,	  we	  profiled	   the	  heparan	   sulfate	   (HS)	  polysaccharide	   side	   chains	  by	  anti-­‐HS	   mAbs	   and	   their	   binding	   capacity	   for	   FGF2	   and	   L-­‐selectin.	   Functionally,	   we	  investigated	   the	   HSPG	   involvement	   of	   FGF2-­‐driven	   mesangial	   proliferation.	   Our	   data	  indeed	   indicate	   spatial	   proteoglycan	   involvement	   in	   CTD,	  which	  might	   be	   a	   potential	  target	  for	  future	  intervention	  therapy.	  	  
	  
Materials	  and	  Methods	  
Rats	  	  Inbred	  female	  (175-­‐210	  gram)	  Dark	  Agouti	  (DA)	  rats	  were	  obtained	  from	  Harlan	  (Horst,	  The	  Netherlands)	  and	  inbred	  male	  Wistar	  Furth	  (WF)	  rats	  (240-­‐295	  gram)	  from	  Charles	  River	   Laboratories	   Inc.	   (l’Arbresle,	   Cedex,	   France).	   All	   animals	   received	   care	   in	  compliance	  with	   the	  Principles	  of	  Laboratory	  Animal	  Care	   (NIH	  Publication	  No.86-­‐23,	  revised	   1985),	   the	   University	   of	   Groningen	   guidelines	   for	   animal	   husbandry	   and	   the	  Dutch	  Law	  on	  Experimental	  Animal	  Care.	  	  	  	  
Kidney	  transplantation	  and	  experimental	  groups	  	  Female	  DA	  kidney	   allografts	  were	   orthotopically	   transplanted	   into	  male	  Wistar	   Furth	  recipients	  as	  described	  previously	  (5,25,26).	  Cold	  ischemic	  times	  ranged	  from	  16	  to	  38	  min.	  Warm	  ischemic	  time	  ranged	  from	  19	  to	  32	  min.	  Recipients	  received	  cyclosporine	  A	  (5	  mg/kg	  BW;	  Sandimmune,	  Novartis,	  the	  Netherlands)	  subcutaneously	  on	  the	  first	  10	  days	   after	   transplantation.	   The	   contralateral	   kidney	  was	   removed	   8	   to	   14	   days	   after	  transplantation.	   Total	   follow-­‐up	   was	   12	   weeks	   or	   shorter	   in	   case	   animals	   had	   to	   be	  sacrificed	  due	  to	  renal	   failure.	  Allografts	  used	   in	  this	  study	  had	  developed	  severe	  CTD	  (n=5).	   Further	   characteristics	   of	   the	   model	   are	   described	   elsewhere	   (5,25,26).	   Non-­‐transplanted	   DA	   kidneys	   (n=5)	   and	   DA	   to	   DA	   isografted	   kidneys	   (n=5)	   served	   as	  controls.	  	  
Laser	  Microdissection	  and	  Gene	  Expression	  Analysis	  Laser	   microdissection,	   RNA	   isolation	   and	   qRT-­‐PCR	   were	   performed	   essentially	  according	  to	  Asgeirsdottir	  et	  al.	  (27).	  Glomeruli	  and	  various	  layers	  (including	  media	  and	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neointima)	   of	   larger	   arteries	   were	   separately	   dissected	   from	   9	   serial	   sections	   per	  kidney.	   An	   average	   of	   194	   [range	   71-­‐308]	   glomeruli	   and	   63	   [range	   25-­‐117]	   arteries	  were	  dissected	  from	  each	  kidney.	  We	  thus	  isolated	  glomeruli	  and	  various	  arterial	  layers	  from	  5	  allografted	  kidneys,	  from	  5	  isografted	  kidneys,	  and	  from	  5	  control	  kidneys.	  	  Total	  RNA	  was	  also	  isolated	  from	  whole	  kidney	  sections	  (n=3	  from	  allograft,	  n=3	  from	  isograft	   and	   n=3	   from	   control	   groups).	   Total	   RNA	   was	   isolated	   from	   microdissected	  structures	  and	  whole	  kidney	  by	  using	  the	  RNeasy	  Micro	  Kit	  (Qiagen,	  Hilden,	  Germany).	  Reverse	   transcription	   was	   carried	   out	   using	   Superscript	   III	   reverse	   transcriptase	  (Invitrogen,	  Breda,	   the	  Netherlands)	   and	   random	  hexamer	  primers	   (Promega,	   Leiden,	  the	  Netherlands).	  Gene	  expression	  was	  analyzed	  with	  a	  custom	  made	  microfluidic	  card-­‐based	  low	  density	  array	  (Applied	  Biosystems,	  Nieuwerkerk	  a/d	  IJssel,	  the	  Netherlands)	  using	   the	   ABI	   Prism	   7900HT	   Sequence	   Detection	   System	   (Applied	   Biosystems,	  Nieuwerkerk	   a/d	   IJssel,	   the	   Netherlands).	   Relative	   mRNA	   levels	   were	   calculated	   as	  2−ΔCT,	   in	  which	   ΔCT	   is	   CTgene	   of	   interest	   –	   CTβ-­‐actin.	   CT-­‐values	   that	  were	   beyond	   detection	  level	  were	  set	  manually	  to	  50.	  Composition	  of	  the	  low	  density	  array	  is	  indicated	  in	  Table	  1.	  
Table	  1.	  Composition	  of	  low-­‐density	  array	  
Gene	  name	   General	  name	  
Gene	  
symbol	   Assay	  ID	  
Matrix	  molecules	   	   	   	  collagen,	  type	  I,	  alpha	  1	   Collagen	  I	   Col1a1	   Rn01463848_m1	  collagen,	  type	  IV,	  alpha	  1	   Collagen	  IV	   Col4a1	   Rn01482925_m1	  	   	   	   	  
Proteoglycans	   	   	   	  perlecan	   Perlecan	   LOC313641	   Rn01515780_g1	  agrin	   Agrin	   Agrn	   Rn00598349_m1	  versican	   Versican	   Vcan	   Rn01493755_m1	  biglycan	   Biglycan	   Bgn	   Rn00567229_m1	  syndecan	  1	   Syndecan	  1	   Sdc1	   Rn00564662_m1	  syndecan	  4	   Syndecan	  4	   Sdc4	   Rn00561900_m1	  	   	   	   	  
Growth	  factors	  	   	   	   	  fibroblast	  growth	  factor	  2	   FGF2	   Fgf2	   Rn00570809_m1	  transforming	  growth	  factor,	  beta	  1	   Tgf-­‐b1	   Tgfb1	   Rn01475963_m1	  	   	   	   	  
Reference	  genes	   	   	   	  beta	  actin	   Beta-­‐actin	   Actb	   Rn00667869_m1	  beta	  2	  microglobulin	   B2m	   B2m	   Rn00560865_m1	  Eukaryotic	  18S	  rRNA	   18S	   18s	   Hs99999901_s1	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Single	  and	  double	  immunofluorescence	  for	  proteoglycans	  and	  FGF2	  on	  rat	  kidney	  
sections	  	  Four	  µm	  frozen	  sections	  were	  fixed	  in	  acetone	  or	  4%	  formaldehyde	  and	  were	  blocked	  for	   endogenous	   peroxidase	   activity	   with	   0.03%	   H2O2	   if	   appropriate.	   Sections	   were	  blocked	   with	   normal	   goat	   or	   rabbit	   serum.	   Sections	   were	   incubated	   for	   1h	   with	   the	  following	  primary	  antibodies:	  mouse	  anti-­‐human	  FGF2	  (Peprotech,	  London,	  UK),	  mouse	  anti-­‐HS	   mAb	   JM-­‐403,	   (28),	   mouse	   anti-­‐HS	   stub	   mAb	   3G10	   (Seikagaku,	   Tokyo,	   Japan;	  (29))	   and	   mouse	   anti-­‐rat	   perlecan	   (clone10B2	   kindly	   provided	   by	   Prof.	   dr.	   J.R.	  Couchman,	   Copenhagen,	   Denmark).	   Binding	   of	   primary	   antibodies	   was	   detected	   by	  incubating	   the	   sections	   for	  30	  min	  with	   secondary	  antibodies	  diluted	   in	  PBS	  with	  5%	  normal	  rat	  serum:	  goat	  anti-­‐mouse	  IgG1	  HRP	  (Southern	  Biotech,	  Birmingham,	  AL,	  USA),	  rabbit	   anti-­‐mouse	   IgM	   HRP(DAKO,	   Heverlee,	   Belgium,),	   or	   goat	   anti-­‐mouse	   IgG1	  Alexa488	   (Invitrogen-­‐Molecular	   Probes,	   Breda,	   the	   Netherlands).	   HRP-­‐activity	   was	  visualized	  using	   the	  TSATM	  Tetramethylrhodamine	   System	   (PerkinElmer	  LAS	   Inc.).	  All	  fluorescence	   microscopy	   was	   performed	   using	   a	   Leica	   DMLB	   microscope	   (Leica	  Microsystems,	   Rijswijk,	   the	   Netherlands)	   equipped	   with	   a	   Leica	   DC300F	   camera	   and	  Leica	  QWin	  2.8	  software.	  	  	  
Detection	  of	  proliferating	  mesangial	  cells	  using	  Ki67	  in	  rat	  kidney	  sections	  Four	   µm	   frozen	   sections	   were	   fixed	   in	   2%	   paraformaldehyde	   (10	   min.)	   followed	   by	  permeabilization	  in	  0.5%	  Triton	  X-­‐100	  for	  5	  min.	  Sections	  were	  incubated	  for	  1h	  with	  mouse	  anti-­‐rat	  perlecan	  (mIgG1,	  clone10B2)	  or	  a	  cocktail	  of	  mouse-­‐anti-­‐rat	  CD90	  [Thy-­‐1]	  (mIgG1,	  clone	  OX7,	  tissue	  culture	  supernatant)	  and	  polyclonal	  rabbit-­‐anti-­‐Ki67	  (NCL-­‐Ki67p,	   Novocastra)	   antibodies.	   Following	   primary	   antibody	   incubation,	   sections	  were	  blocked	  for	  endogenous	  peroxidase	  activity	  with	  0.03%	  H2O2	  if	  appropriate.	  Binding	  of	  primary	  antibodies	  was	  detected	  by	  incubating	  the	  sections	  for	  30	  min	  with	  appropriate	  secondary	  antibodies	  diluted	  in	  PBS/1%BSA	  with	  3%	  normal	  rat	  serum.	  The	  following	  secondary	  antibodies	  were	  used:	  goat	  anti-­‐mouse	  IgG1	  Alexa488	  (Invitrogen-­‐Molecular	  Probes,	   Breda,	   the	   Netherlands)	   and	   goat	   anti-­‐rabbit	   IgG	   HRP	   (DAKO,	   Heverlee,	  Belgium).	  HRP-­‐activity	  was	  visualized	  using	   the	  TSATM	  Tetramethylrhodamine	  System	  (PerkinElmer	   LAS	   Inc.).	   Nuclei	   were	   counterstained	   wth	   DAPI.	   Slides	   were	   mounted	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with	   Aqua	   PolyMount	   (Polysciences,	  Warrington,	   USA).	   Images	  were	   acquired	  with	   a	  Zeiss	   AxioObserver	   Z1	   inverted	   microscope	   equipped	   with	   TissueFAXS	   acquisition	  software	  (Tissuegnostics,	  Vienna,	  Austria).	  	  
Ligand	  binding	  assays	  on	  rat	  kidney	  sections	  	  To	  detect	  capacity	  of	  renal	  proteoglycans	  to	  bind	  FGF2,	  formalin-­‐fixed	  rat	  renal	  sections	  were	  incubated	  with	  recombinant	  human	  FGF2	  (1	  µg/ml;	  Peprotech)	  for	  60	  min.	  After	  washing,	  the	  staining	  was	  continued	  according	  to	  the	  FGF2	  staining	  protocol	  described	  above.	   Formalin	   fixation	   essentially	   avoids	   recognition	   of	   endogenous	   renal	   FGF2	   by	  anti-­‐FGF2	   antibodies.	   Likewise,	   paraformaldehyde-­‐fixed	   rat	   renal	   sections	   were	  incubated	  with	  L-­‐selectin-­‐Fc	  recombinant	  chimeric	  protein	  (1	  µg/ml)	  and	  visualized	  as	  described	  previously	  (30).	  To	  confirm	  that	  the	  observed	  binding	  pattern	  was	  mediated	  by	   HS	   proteoglycans,	   the	   sections	   were	   pretreated	   with	   0.05	   U/ml	   heparitinase	   I	  (Flavobacterium	   heparinum,	   EC	   4.2.2.8;	   Seikagaku,	   Tokyo,	   Japan)	   for	   1h	   at	   37°C	   in	   a	  humidified	  chamber.	  	  	  	  
FGF2	  binding	  assays	  in	  ELISA	  In	  an	  ELISA	  approach	  we	  evaluated	  the	  capability	  of	  fluid	  phase	  HS-­‐like	  polysaccharides	  to	   compete	   for	   the	   interaction	   of	   recFGF2	   with	   immobilized	   perlecan.	   To	   this	   end,	  maxisorp	  96-­‐wells	  plates	  (U96	  from	  VWR	  International,	  Amsterdam,	  The	  Netherlands)	  were	  coated	  overnight	  in	  PBS	  with	  5	  µg/ml	  perlecan	  (Sigma).	  After	  washing	  in	  PBS	  with	  0.05%	  Tween	  20,	  wells	  were	  blocked	  with	  5%	  skimmed	  milk	  powder	   in	  Tris	  buffered	  saline	  (TBS)	  for	  1	  h.	  In	  a	  separate	  microtiter	  plate,	  recFGF2	  (0.5	  µg/ml)	  was	  incubated	  for	  30	  min	  with	  a	  dilution	  range	  of	  different	  HS-­‐like	  polysaccharides	  and	  transferred	  to	  the	  ELISA	  plate	  after	  the	  wells	  were	  washed	  again.	  Incubation	  in	  the	  wells	  took	  1	  h.	  The	  wells	  were	  washed	  again	  and	  monoclonal	  mouse	  anti-­‐FGF2	  antibodies	  were	  added	   to	  the	  wells	   (0.5	   µg/ml	   TBS-­‐Tween	   20).	   Secondary	   antibody	  was	   added	   after	   a	  washing	  step	  (HRP-­‐labeled	  rabbit	  anti-­‐mouse	  IgG,	  1:5000;	  DAKO,	  Glostrup,	  Denmark).	  Secondary	  antibody	  was	  detected	  with	  3,3’,5,5’-­‐tetramethylbenzidine	  substrate	  (Sigma)	  for	  15	  min	  in	   the	   dark,	   and	   the	   reaction	   was	   stopped	   by	   adding	   1.5	   N	   H2SO4.	   Absorbance	   was	  measured	  at	  450	  nm	  in	  a	  microplate	  reader.	  All	   incubations	  were	  done	  in	  a	  volume	  of	  100	  µl/well	  at	  RT.	  Polysaccharides	  used	  in	  the	  FGF2	  competition	  ELISA	  were:	  heparin	  from	   porcine	   intestinal	   mucosa	   (Sigma),	   HS	   from	   bovine	   kidney	   (Seikagaku,	   Tokyo,	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Japan),	  N-­‐sulfation	  of	  HS	  from	  bovine	  kidney	  was	  done	  as	  described	  before	  (8),	  N-­‐	  and	  O-­‐desulfation	  of	  heparin	   from	  porcine	   intestine	  was	  done	  as	  described	  before	   (8).	  HS	  from	   human	   aorta	   was	   isolated	   essentially	   according	   to	   Iverius	   (31).	   HS	   from	   EHS	  sarcoma	   was	   from	   Seikagaku	   (Tokyo,	   Japan).	   In	   order	   to	   evaluate	   FGF2	   binding	   by	  perlecan	  from	  renal	  lysates	  a	  slightly	  modified	  ELISA	  approach	  was	  followed.	  Perlecan	  from	   renal	   lysates	   (10	   µg	   protein/ml	   carbonate	   buffer)	   was	   immunocaptured	   on	  monoclonal	   mouse	   anti-­‐rat	   perlecan	   antibody	   (mAb	   10B2	   from	   John	   Couchman,	  Copenhagen,	  Denmark;	  1:1000	  in	  PBS)	   immobilized	   in	  Maxisorp	  96-­‐wells	  plates.	  After	  appropriate	  blocking,	  captured	  renal	  perlecan	  was	  incubated	  with	  recFGF2	  (0.5	  µg/ml),	  followed	   by	   biotinylated	   anti-­‐FGF2	   mAb	   (clone	   JKFb-­‐2	   from	   Novus	   Biologicals,	  Cambridge,	   UK.;	   1	   µg/ml	   TBS-­‐T),	   followed	   by	  HRP-­‐conjugated	   streptavidin,	   1:5000	   in	  TBS-­‐T.	  Substrate	  reaction	  and	  plate	  reading	  was	  as	  described	  above.	  	  	  	  	  
FGF2	  stimulation	  assay	  on	  rat	  mesangial	  cells	  	  Rat	  mesangial	  cells	  (Thy	  1.1,	  perlecan	  and	  α-­‐smooth	  muscle	  actin	  positive,	  passage	  11-­‐15)	   were	   cultured	   in	   24	  well	   plates	   in	   Dulbecco’s	  modified	   Eagle’s	  medium	   (DMEM)	  supplemented	  with	  25	  mM	  HEPES,	  4.5	  mg/ml	  glucose,	  pyridoxine,	  1	  mM	  pyruvate,	  50	  ng/ml	   insulin,	   and	   10%	   fetal	   bovine	   serum.	   Before	   stimulation	  with	   FGF2	   cells	  were	  grown	   until	   confluency,	   serum	   deprived	   (0.5%	   serum)	   for	   24	   h	   and	   subsequently	  incubated	   with	   different	   concentrations	   (0.031	   –	   8	   ng/ml)	   of	   FGF2	   for	   24	   h.	  Proliferation	   was	   measured	   by	   adding	   0.5	   µCi/ml	   3H-­‐thymidine	   (Amersham,	  Buckinghamshire,	   UK)	   for	   24	   h	   to	   the	   cultures.	   After	   24	   h,	   5%	   trichloric	   acid	  precipitable	  material	  was	  dissolved	   in	  0.1%	  SDS,	  Optiphase	  “HiSafe	  3”	  was	  added	  and	  radioactivity	   was	   counted	   in	   a	   1214	   Rackbeta	   liquid	   scintillation	   counter.	   To	   study	  whether	  FGF2-­‐induced	  proliferation	  of	  mesangial	  cells	  was	  reduced	  in	  the	  presence	  of	  exogenous	  HS,	  mesangial	  cells	  were	  stimulated	  with	  0.5	  ng/ml	  FGF2	  for	  24	  hours	  in	  the	  presence	  of	  various	  concentrations	  (0,	  8,	  32	  and	  128	  µg/ml)	  exogenous	  HS	  from	  bovine	  kidney	   [HSBK]	   (Seikagaku,	   Tokyo,	   Japan).	   Proliferation	   was	   measured	   as	   described	  above.	   To	   study	   whether	   proteoglycan	   sulfation	   was	   reduced	   by	   chlorate,	   mesangial	  cells	  were	  cultured	  for	  24	  hrs	  in	  the	  presence	  of	  various	  concentrations	  (5-­‐25	  mM)	  Na-­‐chlorate	   (Sigma)	   and	   35S-­‐sulfate	   (2	   µCi/ml;	   Amersham,	   Buckinghamshire,	   UK).	  Incorporation	   of	   35S-­‐sulfate	   into	   proteoglycans	   was	   quantified	   similarly	   as	   described	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above	   for	   3H-­‐thymidine	   incorporation.	   Finally,	   to	   analyze	   whether	   chlorate	   impairs	  FGF2-­‐induced	   proliferation	   of	   mesangial	   cells,	   cells	   were	   stimulated	   with	   FGF2	   (0.5	  ng/ml)	  for	  fixed	  times	  (0,	  0.5,	  1,	  2,	  4	  and	  24	  hrs)	  in	  the	  presence	  or	  absence	  of	  25	  mM	  Na-­‐chlorate	  and	  in	  the	  presence	  of	  0.5	  µCi/ml	  3H-­‐thymidine.	  Total	  culture	  time	  was	  24	  hrs.	   Proliferation	   was	   determined	   as	   described	   above.	   Before	   stimulation	   with	   FGF2	  cells	   were	   grown	   until	   confluency,	   serum	   deprived	   (0.5%	   serum)	   for	   24	   h	   and	  subsequently	  incubated	  with	  FGF2	  for	  24	  h.	  Proliferation	  was	  measured	  by	  adding	  0.5	  µCi/ml	  3H-­‐thymidine	  (Amersham,	  Buckinghamshire,	  UK)	  for	  24	  h	  to	  the	  cultures.	  After	  24	   h,	   5%	   trichloric	   acid	   precipitable	   material	   was	   dissolved	   in	   0.1%	   SDS,	   Optiphase	  “HiSafe	   3”	   was	   added	   and	   radioactivity	   was	   counted	   in	   a	   1214	   Rackbeta	   liquid	  scintillation	   counter.	   Incorporation	   of	   35S-­‐sulfate	   into	   proteoglycans	   was	   quantified	  similarly	  as	  described	  above	  for	  3H-­‐thymidine	  incorporation.	  	  
	  
Detection	  of	  perlecan	  expression	  on	  proliferating	  rat	  mesangial	  cells	  Rat	   mesangial	   cells	   were	   cultured	   as	   described	   above.	   After	   expansion,	   cells	   were	  seeded	   on	   coverslips	   and	   serum	   starved	   for	   24	   hrs	   in	   medium	   containing	   0.5%	   FCS	  following	   attachment.	   Subsequently,	   cells	   were	   stimulated	   for	   48	   hrs	   in	   medium	  containing	   either	   2%	   or	   10%	   FCS.	   After	   stimulation,	   cells	   were	   fixed	   in	   2%	  paraformaldehyde	   and	   double	   stained	   for	   α-­‐SMA	   (mIgG2a,	   clone	   1A4,	   DAKO)	   and	  perlecan	   (mIgG1,	   clone10B2)	   as	   described	   above.	   Binding	   of	   primary	   antibodies	  was	  detected	  by	  incubating	  the	  sections	  for	  30	  min	  with	  goat	  anti-­‐mouse	  IgG1	  Alexa488	  and	  goat	  anti-­‐mouse	  IgG2a	  Alexa555	  (both	  from	  Invitrogen-­‐Molecular	  Probes).	  Nuclei	  were	  counterstained	  wth	  DAPI.	   Slides	  were	  mounted	  with	   Aqua	   PolyMount	   (Polysciences).	  Confocal	  microscopy	  was	  performed	  using	  a	   Inverted	  microscope	  Zeiss	  LSM	  780	  NLO	  (Axio	  Observer.Z1)	  microscope.	  In	  order	  to	  quantify	  total	  cell	  numbers	  and	  numbers	  of	  perlecan	   expressing	   mesangial	   cells,	   coverslips	   were	   scanned	   using	   TissueFAXS	  acquisition	  software	  (Tissuegnostics)	  on	  a	  Zeiss	  AxioObserver	  Z1	  inverted	  microscope.	  Quantitative	   analyses	   were	   performed	   using	   TissueQuest	   fluorescence	   analysis	  software	  (Tissuegnostics).	  
	  	  
Statistics	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mRNA	  expression	  levels	  were	  analyzed	  using	  a	  one-­‐way	  ANOVA	  with	  Turkey’s	  post-­‐hoc	  test.	   P	   values	   of	   <0.05	   were	   considered	   statistically	   significant	   (SPSS®	   software	  package).	   Statistical	   outliers,	   as	   detected	   by	   Grubbs'	   test	   for	   outliers,	   were	   excluded	  from	  analyses.	  Mesangial	  cell	  culture	  data	  were	  expressed	  as	  mean	  ±	  standard	  error	  of	  the	   mean	   (SEM)	   and	   analyzed	   by	   one-­‐way	   ANOVA.	   If	   overall	   p<0.05,	   Bonferroni’s	  Multiple	   Comparison	   Test	   was	   performed	   (GraphPad	   Prism	   5.0,	   GraphPad	   Software,	  Inc.).	  	  
Results	  
	  
Development	  of	  chronic	  transplant	  dysfunction	  in	  renal	  allografts	  Progressive	  renal	  function	  loss	  was	  evidenced	  in	  the	  allografted	  kidneys	  by	  a	  ∼50%	  loss	  in	  creatinine	  clearance	  and	  a	  ∼15-­‐fold	  rise	  in	  urinary	  protein	  excretion	  at	  8	  weeks	  after	  transplantation,	  both	  of	  which	  were	  not	  observed	  in	  isografted	  kidneys,	  as	  we	  showed	  before	   in	   this	   model	   (5,25,26).	   Allografted	   rats	   developed	   hypertension	   and	   showed	  development	   of	   severe	   CTD	   with	   FGS	   (Figure	   1A)	   and	   arterial	   neointima	   formation	  (Figure	  1B).	  In	  isografts,	  development	  of	  FGS	  was	  minimal	  and	  no	  neointima	  formation	  was	  observed	  (5,25,26).	  The	  development	  of	  FGS	  coincided	  with	  significantly	  increased	  expression	   of	   the	   pro-­‐fibrotic	   factors	   Col	   Iα1,	   Col	   IVα1	   and	   Tgf-­‐β1	   as	   determined	   by	  qRT-­‐PCR	   on	   microdissected	   glomeruli	   (Figure	   1C).	   These	   molecular	   responses	   were	  also	   observed	   in	   RNA	   isolated	   from	   microdissected	   arterial	   medial	   and	   neointimal	  tissue	  as	  well	  as	  in	  whole	  kidney	  material	  (26).	  These	  data	  confirm	  development	  of	  CTD	  in	  our	  rat	  transplantation	  model.	  	  	  
Induction	  of	  glomerular	  and	  neointimal	  perlecan	  expression	  in	  CTD	  Proteoglycans	   can	   modulate	   growth	   factor	   responses	   by	   virtue	   of	   their	  glycosaminoglycan	   side	   chains.	   Therefore,	   we	   profiled	   the	   matrix	   HS	   proteoglycans	  agrin	  and	  perlecan,	  the	  matrix	  chondroitin	  sulfate-­‐	  and	  dermatan	  sulfate	  proteoglycans	  versican	   and	  biglycan,	   and	   the	  major	   epithelial	   cell	   surface	   proteoglycans	   syndecan-­‐1	  and	   -­‐4	   by	   qRT-­‐PCR.	   PCR	   analysis	   showed	   the	   expression	   of	   the	   basement	  membrane	  HSPG	  perlecan	  to	  be	  upregulated	  mainly	  in	  the	  glomeruli	  (Figure	  2A),	  and	  mediae	  and	  neointimae	  (Figure	  2B)	  of	  the	  allografts.	  This	  spatial	  upregulation	  of	  perlecan	  by	  qRT-­‐PCR	  in	  glomeruli,	  mediae	  and	  neointimae	  was	  however	  not	  observed	  when	  performing	  





Figure	   1.	   Chronic	   transplant	   dysfunction	   in	   renal	   allografts.	   A:	   Representative	   photomicrographs	  showing	  development	  of	  glomerulosclerosis	   in	  allografted	  kidneys,	   in	  contrast	  to	   isografted	  and	  control	  kidneys	   (PAS	   staining).	   B:	   Neointima	   formation	   was	   observed	   in	   allografts	   but	   not	   in	   isografts	   and	  controls	  (Verhoeff	  staining).	  Scale	  bar	  represents	  50	  µm.	  C:	  qRT-­‐PCR	  analysis	  performed	  on	  RNA	  isolated	  from	   microdissected	   glomeruli	   from	   non-­‐transplanted	   control	   tissue,	   isografts	   and	   allografts	  (n=5/group).	  Expression	  levels	  of	  Col	  IVα1,	  Col	  Iα1	  and	  TGF-­‐β1	  are	  expressed	  as	  fold	  increase	  compared	  with	   non-­‐transplanted	   control	   kidneys.	   *	   p<0.05;	   **	   p<0.01;	   ***	   p<0.001.	   Abbreviations:	   IEL:	   internal	  elastic	  lamina,	  M:	  media,	  A:	  adventitia,	  NI:	  neointima	  	  PCR	  in	  glomeruli,	  mediae	  and	  neointimae	  was	  however	  not	  observed	  when	  performing	  qRT-­‐PCR	   analysis	   on	  whole	   kidney	   RNA	   isolates	   (Figure	   2C).	   Thisclearly	   stresses	   the	  power,	   and	   need,	   of	   using	   microdissection	   of	   specific	   structures	   to	   demonstrate	  differential	   proteoglycan	   expression	   in	   specific	   renal	   compartments.	   Using	  immunofluorescence,	   expression	   of	   perlecan	   was	   virtually	   absent	   in	   the	   glomerular	  basement	  membranes	  of	  non-­‐transplanted	  control	  kidneys.	  In	  the	  glomerular	  basement	  membranes	   of	   isografts,	   perlecan	   expression	   was	   increased	   compared	   with	   control	  kidneys,	  but	  to	  a	  far	  lesser	  extent	  than	  the	  increase	  observed	  in	  allografts	  (Figure	  2D).	  In	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glomeruli	  with	   FGS	   in	   allografts	   a	   strong	   expression	   of	   perlecan	  was	   observed	   in	   the	  glomerular	   basement	  membranes	   and	  mesangial	   areas	   (Figure	   2D).	   In	   control	   tissue,	  isografts	   and	   allografts	   the	   Bowmans	   capsule	   was	   positive	   for	   perlecan.	  Immunofluorescence	   also	   showed	   perlecan	   expression	   in	   the	  mediae	   and	   the	   newly-­‐formed	   neointimae	   present	   in	   allografts	   (Figure	   2D,	   right	   column).	   Quantification	   of	  glomerular	  perlecan	  expression	  by	  digital	  image	  analysis	  revealed	  a	  significant	  increase	  in	   perlecan	   expression	   in	   the	   glomeruli	   of	   allografted	   kidneys	   compared	   to	   isografts	  (p<0.01)	  and	  non-­‐transplanted	  kidneys	  (p<0.01)	  (Figure	  2E).	  No	  significant	  differences	  in	   expression	   levels	  were	   found	   for	   syndecan-­‐1	   and	   -­‐4,	   agrin,	   and	   biglycan,	   although	  these	   proteoglycans	   were	   expressed	   in	   the	   neointimae	   based	   on	   qRT-­‐PCR	   data	  (Supplemental	   figure	   1A-­‐E).	   Versican	   expression	  was	   significantly	   upregulated	   in	   the	  media	  of	  the	  allografted	  kidneys	  (Supplemental	  figure	  1E	  middle	  panel),	  which	  is	  in	  line	  with	  a	  pro-­‐migratory	  phenotype	  of	  the	  vascular	  smooth	  muscle	  cells.	  This	  proteoglycan	  profiling	   led	  us	  to	  conclude	  that	  glomerular	  and	  neointimal	  perlecan	  is	  upregulated	  in	  renal	  allografts	  at	  both	  the	  mRNA	  and	  protein	  level.	  	  
Heparan	  sulfate	  profiling	  Since	  HS	  proteoglycans	  are	  involved	  in	  morphogenesis	  and	  tissue	  remodeling	  mainly	  by	  their	   HS	   glycosaminoglycan	   side	   chains,	   we	   profiled	   HS	   polysaccharide	   structures	   in	  renal	  sections.	  To	  this	  end	  we	  visualized	  HS	  epitopes	  by	  anti-­‐HS	  mAbs	  JM-­‐403	  and	  3G10,	  and	  by	  a	  tissue	  ligand	  binding	  assay	  using	  the	  HS-­‐binding	  growth	  factor	  FGF2	  and	  HS-­‐binding	  adhesion	  molecule	  L-­‐selectin.	  Characteristics	  of	  the	  corresponding	  HS-­‐epitopes	  	  are	  detailed	  in	  Table	  2.	  Anti-­‐HS	   mAb	   JM-­‐403	   demonstrated	   a	   clear	   staining	   of	   the	   glomerular	   basement	  membranes	  in	  control	  and	  isografted	  kidneys	  (Figure	  3A).	  Mesangial	  staining	  was	  weak	  for	   mAb	   JM-­‐403.	   In	   allografts	   however,	   glomerular	   JM-­‐403	   HS	   staining	   is	   partly	   or	  completely	  lost	  in	  sclerotic	  areas	  (Figure	  3A),	  likely	  due	  to	  increased	  HS	  sulfation.	  	  Figure	  3A	   (most	   right	  panel)	   represents	   JM-­‐403	  staining	   (brown)	   combined	  with	  PAS	  histochemistry.	  PAS-­‐positive	  sclerotic	   tissue	  was	   indeed	  negative	   for	  anti-­‐HS	  mAb	   JM-­‐403.	  The	  3G10	  HS	  epitope,	  which	  becomes	  available	  after	  heparitinase	  cleavage	  of	  HS,	  is	  absent	   in	   the	   glomerular	   basement	   membranes	   of	   control	   kidneys,	   becomes	   weakly	  expressed	  in	  the	  isografted	  kidneys,	  and	  is	  strongly	  upregulated	  in	  glomerular	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Table2.	   Basic	   characteristics	   of	   the	   HS	   epitopes	   recognized	   by	   the	   anti-­‐HS	   mABs,	   by	  FGF2	  and	  by	  L-­‐selectin	  
	  	  
	   	  	  	  
Anti-­‐HS	  mAb	  or	  HS-­‐binding	  
protein	   Basic	  characteristics	  of	  the	  HS	  epitope	  
Anti-­‐HS	  mAb	  JM-­‐403	   GlcUA-­‐rich	  sequences	  with	  N-­‐unsubstituted	  GlcN	  units	  in	  low	  sulfated	  HS	  (28)	  	  Anti-­‐HS	  mAb	  3G10	  	   	  Desaturated	  Uronate	  residues	  after	  digestion	  with	  heparitinase	  (GlcNAc/NS	  α1-­‐4	  GlcA	  linkage;	  (25))	  	  FGF2	  	   L-­‐selectin	  	  
2-­‐O	  sulfation	  in	  heparin	  and	  HS	  (29)	  	  6-­‐O	  sulfated	  GlcN	  units	  in	  HS	  and	  heparin	  (42)	  
 Chapter 6 
133 
Figure	  2.	  Upregulation	  of	  perlecan	  in	  glomeruli	  and	  neointimae	  of	  renal	  allografts	  with	  CTD.	  A-­‐C.	  Perlecan	  expression	  measured	  by	  qRT-­‐PCR	   in	   glomeruli	   (n=5/group)	   (A),	   arterial	  mediae	   (n=5/group)	  
(B),	  and	  whole	  kidney	  tissue	  (n=3/group)	  (C).	  Expression	  levels	  of	  perlecan	  are	  expressed	  as	  fold	  change	  compared	   with	   non-­‐transplanted	   control	   kidneys.	   D:	   Immunofluorescence	   demonstrating	   perlecan	  accumulation	  in	  glomeruli	  (top	  panel)	  and	  neointimae	  (lower	  panel)	  of	  allografts	  with	  CTD.	  In	  isografted	  kidneys	  a	  minor	  increase	  of	  perlecan	  was	  seen	  in	  glomeruli	  and	  arterial	  media	  compared	  to	  control	  tissue.	  Dotted	   line	   represents	   the	   internal	   elastic	   lamina.	   Scale	   bar	   represents	   50	   µm.	   E:	   Quantification	   of	  glomerular	   perlecan	   expression	   by	   digital	   image	   analysis	   showed	   significant	   increase	   in	   allografted	  kidneys.	  **	  p<0.01;	  ***	  p<0.001.	  	  	  
	  	  
Figure	  3.	  Modification	  of	  glomerular	  HS	  structure	  in	  allografts	  with	  CTD.	  Glomerular	  expression	  of	  HS	  was	  evaluated	  by	  two	  anti-­‐HS	  mAbs	  (JM-­‐403	  [A]	  and	  3G10	  [B])	  as	  well	  as	  by	  the	  binding	  of	  FGF2	  (C)	  and	  L-­‐selectin	   (D).	   In	   allografts,	   glomerular	   JM-­‐403	   staining	   is	  partly	   lost	   in	   sclerotic	   areas	   (A	  arrows).	  This	   is	   evidenced	   by	   loss	   of	   JM-­‐403	   staining	   in	   PAS-­‐positive	   sclerotic	   area	   (A,	   right	   photo).	   On	   the	  contrary	   HS	   expression	   as	   evidenced	   by	   3G10	   (B)	   and	   FGF2	   binding	   capacity	   (C)	   was	   increased	   in	  glomeruli	   in	  allografts.	  L-­‐selectin	  did	  not	  bind	  to	  glomerular	  HS	  of	  control,	   isografted	  or	  allografted	  (D)	  kidneys,	   although	   HS	   in	   Bowman’s	   capsule	   and	   tubular	   basement	   membranes	   did	   bound	   L-­‐selectin.	  Blanks	  (PBS	  control)	  represent	  staining	  of	  allograft	  renal	  tissue	  without	  anti-­‐HS	  mAb	  (A	  and	  B)	  or	  ligand	  binding	  assay	  without	  incubation	  with	  FGF2	  (C)	  or	  L-­‐selectin	  (D).	  Blanks	  are	  shown	  in	  a	  double	  staining	  with	   DAPI	   to	   visualize	   the	   nuclei	   of	   renal	   material.	   Dotted	   line	   represents	   Bowmans	   capsule.	   Arrows	  indicate	  sclerotic	  area.	  Scale	  bars	  represent	  50	  µm	  (indicated	  in	  the	  photo’s).	  	  basement	   membranes	   and	   sclerotic	   areas	   in	   the	   allografts	   (Figure	   3B).	   The	   3G10	  staining	  seems	  to	  colocalize	  with	  perlecan	  (see	  Figure	  4),	  which	  might	  suggest	  this	  HS	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epitope	   to	   be	   expressed	   by	   perlecan.	   FGF-­‐2	   binding	   is	   completely	   HS-­‐dependent	   as	  evidenced	   by	   control	   experiments	   on	   heparitinase	   pretreated	   sections,	   where	   all	  binding	   of	   FGF-­‐2	  was	   lost	   (not	   shown).	   In	   glomeruli	   of	   control	   kidneys	   and	   isografts	  (Figure	   3C)	   FGF-­‐2	   binding	   to	   HS	   was	   absent	   or	   only	   weakly	   present.	   In	   allografts,	  increased	  binding	  of	  FGF-­‐2	  was	  observed	  (Figure	  3C).	  Although	  L-­‐selectin	  clearly	  binds	  to	  HS	  in	  Bowmans	  capsule	  and	  to	  HS	  in	  a	  number	  of	  tubular	  basement	  membranes,	  no	  glomerular	   staining	  was	   observed	   in	   either	   control,	   isografted	   or	   allografted	   kidneys	  (Figure	  3D).	   In	   the	  arterial	  media	  of	  control	  and	   isografted	  kidneys	  moderate	  staining	  for	   anti-­‐HS	  mAbs	   JM-­‐403	   (Figure	   5A)	   and	   3G10	   (Figure	   5B)	   was	   observed,	   however	  binding	  capacity	  for	  FGF2	  (Figure	  5C)	  and	  L-­‐selectin	  (Figure	  5D)	  was	  absent.	  Compared	  to	  the	  mediae	  of	  control	  and	  isografted	  kidneys,	  in	  allografts	  JM-­‐403	  staining	  was	  lost	  in	  the	  media	   (Figure	   5A),	   whereas	   3G10	   staining	  was	   increased	   (Figure	   5B).	   Moreover,	  FGF2	   binding	   capacity	   was	   increased	   in	   the	   allograft	   media	   (Figure	   5C).	   In	   the	  neointimae	  strong	  binding	  of	  anti-­‐HS	  mAbs	  JM-­‐403	  (Figure	  5A)	  and	  3G10	  (Figure	  5B)	  as	  well	  as	  binding	  of	  FGF2	  (Figure	  5C)	  was	  observed.	  L-­‐selectin	  did	  not	  bind	  to	  arterial	  HS	  of	   control,	   isografted,	   and	   allografted	   kidneys	   (Figure	   5D),	   despite	   recognition	   of	   HS	  isoforms	   in	   other	   renal	   structures	   such	   as	   Bowman’s	   capsule	   and	   tubular	   basement	  membranes	  (see	  Figure	  3).	  	  Collectively,	   these	   data	   show	   changes	   in	   glomerular	   and	   arterial	   HS	   composition	   in	  allografts	  with	  CTD,	  with	  loss	  of	  JM-­‐403	  staining	  and	  increased	  FGF2	  binding	  capacity,	  without	   L-­‐selectin	   binding	   capacity,	   which,	   based	   on	   the	   epitope	   requirements	   (see	  Table	  2)	   can	  be	  explained	  by	   increased	  HS	  sulfation,	  most	   likely	  N-­‐	  and	  2-­‐O	  sulfation,	  but	  not	  6-­‐O	  sulfation.	  	  
	  
Figure	   4.	   Perlecan	   and	   3G10	  HS	   double	   staining	   in	   glomeruli	   of	   allografted	   kidneys.	   In	   a	   double	  immunofluorescent	  staining	  protocol,	  perlecan	  (left)	  and	  HS	  (middle;	  evidenced	  by	  mAb	  3G10)	  seem	  ton	  stain	   identical	   structures	   in	   the	   glomerulus,	   namely	   Bowman’s	   capsule,	   the	   thickened	   glomerular	  basement	  membranes	  and	  enlarged	  mesangial	  matrix	  (right	  for	  merged	  photo’s).	  MAb	  3G10	  also	  stained	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some	  tubular	  basement	  membranes	  which	  were	  barely	  perlecan	  positive,	  and	  most	  likely	  recognized	  HS	  bound	  to	  agrin	  and/or	  collagen	  XVIII.	  Scale	  bars	  represent	  50	  µm.	  	  
FGF2	  binding	  to	  perlecan-­‐HS	  requires	  specific	  sulfation	  motifs	  In	   an	   ELISA	   approach	   we	   evaluated	   the	   interaction	   of	   recFGF2	   with	   immobilized	  perlecan	   and	   studied	   competition	   of	   FGF2-­‐perlecan	   interaction	   by	   fluid	   phase	  glycosaminoglycans.	  As	  expected	  heparin	  dose-­‐dependently	  inhibited	  the	  interaction	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   5.	   Modification	   of	   arterial	   HS	   structure	   in	   allografts	   with	   CTD.	   Medial	   and	   neointimal	  expression	  of	  HS	  was	  evaluated	  by	  two	  anti-­‐HS	  mAbs	  (JM-­‐403	  [A]	  and	  3G10	  [B])	  as	  well	  as	  by	  the	  binding	  of	   FGF2	   (C)	   and	   L-­‐selectin	   (D).	   In	   the	   media	   of	   allografted	   kidneys,	   JM-­‐403	   staining	   was	   largely	   lost,	  whereas	  in	  the	  neointima	  this	  epitope	  was	  clearly	  expressed	  (A,	  right).	  Both	  the	  media	  and	  neointima	  of	  the	  allografts	  expressed	  the	  3G10	  HS	  epitope	  (B,	  right).	  The	  media	  and	  neointima	  bound	  FGF2	  (C,	  right),	  but	  no	  L-­‐selectin	  (D,	  right).	  Negative	  controls	  are	  shown	  in	  Figure	  3.	  Although	  L-­‐selectin	  did	  not	  bound	  to	  arteries,	  HS-­‐dependent	   binding	  was	   seen	   in	  Bowman’s	   capsule	   and	   tubular	   basement	  membranes	   (see	  Figure	  3).	  Scale	  bars	  represent	  50	  µm,	  as	  indicated	  in	  the	  Figure.	  	  FGF2	  with	  the	  HS	  side	  chains	  of	  perlecan.	  N-­‐desulfation	  of	  heparin	  largely	  reduced	  the	  inhibitory	  capacity	  of	  heparin,	  and	  O-­‐desulfation	  completely	  prevented	  interaction	  with	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FGF2	   (Figure	   6A).	   Dose-­‐dependent	   inhibition	   was	   also	   achieved	   by	   HS	   isolated	   from	  bovine	  kidney,	  although	  to	  a	  lesser	  extent	  than	  heparin.	  N-­‐deacetylation	  followed	  by	  N-­‐resulfation	  of	  HS	   from	  bovine	  kidney	   increased	   the	   inhibitory	  capacity	   clearly	   (Figure	  6B),	  whereas	   low	   sulfated	  HS	   from	  mouse	  EHS	   tumor	  or	   from	  human	  aorta	   inhibited	  FGF2-­‐perlecan	  interaction	  to	  some	  extent	  or	  not	  at	  all.	  These	  data	  show	  that	  the	  degree	  of	  sulfation	  of	  HS/heparin	  polysaccharides	  determines	  interaction	  with	  FGF2.	  	  
	  	  	  	  	  	   	  
Figure	  6.	   FGF2	  binding	   to	  perlecan.	   Inhibition	  of	   the	  binding	  of	   recFGF2	   to	   immobilized	  perlecan	  by	  fluid	   phase	   GAGs	   was	   measured	   in	   ELISA	   (A	   and	   B).	   Heparin	   dose-­‐dependently	   inhibited	   FGF2	   from	  binding	   to	   immobilized	  perlecan.	  N-­‐desulfated	  heparin	   largely	   lost	   inhibitory	  capacity	  and	  O-­‐desulfated	  heparin	   completely	   lost	   binding	   to	   FGF2	   (A).	   HS	   from	  bovine	   kidney	   dose-­‐dependently	   inhibited	   FGF2	  binding	   to	   perlecan	   (B).	  N-­‐sulfated	  HS	   from	  bovine	   kidney	   increased	   binding	   capacity	   to	   FGF2.	   On	   the	  contrary,	  two	  lower	  sulfated	  HS	  preparations	  (from	  EHS	  sarcoma	  and	  from	  human	  aorta)	  bound	  poorly	  with	   FGF2.	   C:	   FGF2	   binding	   to	   antibody-­‐captured	   perlecan	   from	   renal	   lysates	   show	   increased	   FGF2	  binding	  to	  perlecan	  from	  allografted	  kidneys	  compared	  to	  perlecan	  from	  control	  kidneys.	  **:	  p<0.01	  	  In	   a	   next	   experiment	  we	   evaluated	   the	   FGF2	   binding	   capacity	   of	   perlecan	   selectively	  adsorbed	  	  from	  renal	  lysates	  by	  immobilized	  anti-­‐rat	  perlecan	  mAb	  in	  ELISA	  plates.	  We	  found	  that	  perlecan	  from	  allografted	  kidneys	  bound	  substantially	  more	  FGF2	  compared	  to	   perlecan	   from	   control	   kidneys	   (p<0.01;	   Figure	   6C),	   which	   is	   due	   to	   increased	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sulfation	  and/or	  content	  of	  perlecan	  from	  allografted	  kidneys.	  	  	  	  
Endogenous	  expression	  of	  FGF2	  in	  allografts	  with	  CTD	  We	  next	  evaluated	  endogenous	  expression	   levels	  of	  FGF2.	   In	  control	  kidneys,	  we	  only	  observed	   weak	   segmental	   FGF2	   expression	   in	   the	   glomeruli	   (Figure	   7A),	   and	   the	  tubulointerstitium	   (Figure	   7A).	   Arteries	   (Figure	   7B)	   were	   devoid	   of	   any	   FGF2	  expression.	   In	   isografts,	   a	   slight	   upregulation	   of	   FGF2	   expression	   in	   glomeruli	   was	  observed	   (Figure	   7A),	   with	   the	   arteries	   remaining	   devoid	   of	   any	   FGF2	   expression	  (Figure	   7B).	   However,	   in	   the	   allografts,	   FGF2	   was	   strongly	   and	   homogeneously	  accumulated	  throughout	  the	  glomeruli,	  and	  present	  mainly	  in	  the	  glomerular	  capillary	  wall	   and	   mesangium	   (Figure	   7A).	   Quantification	   of	   FGF2	   staining	   by	   digital	   image	  analysis	  (Figure	  7C,	  left)	  revealed	  a	  strong	  increased	  FGF2	  expression	  in	  the	  glomeruli	  of	   allografted	  kidneys	   compared	   to	   isografted	  kidneys	   (p<0.02)	   and	  non-­‐transplanted	  control	  kidneys	  (p<0.01).	  PCR	  analysis	  showed	  no	  significant	  differences	  in	  glomerular	  FGF2	  expression,	  although	  a	  tendency	  towards	  higher	  expression	  was	  observed	   in	  the	  allografts	   (Figure	   7C,	   right).	   We	   suggest	   that	   this	   discrepancy	   may	   be	   explained	   by	  plasma-­‐derived	   FGF2	   being	   trapped	   in	   the	   glomeruli	   by	   perlecan	   endowed	   with	   HS	  chains	  able	  to	  bind	  FGF2	  (as	  shown	  in	  Figure	  3)	  during	  ultrafiltration.	  This	  would	  cause	  local	  accumulation	  of	  FGF2	  protein	  in	  the	  absence	  of	  an	  increase	  in	  mRNA	  expression.	  In	  addition,	   in	   the	   neointimae	   of	   allografts	   increased	   FGF2	   expression	   was	   observed	   at	  protein	  level	  (Figures	  7B,	  right)	  but	  not	  at	  mRNA	  level	  (Figure	  7D).	  	  
	  	  
Involvement	  of	  proteoglycans	  in	  FGF2-­‐driven	  proliferation	  of	  mesangial	  cells	  To	   explore	   a	   possible	   mechanistic	   relation	   between	   glomerular	   HSPGs	   and	   FGF2	   in	  more	   detail,	   we	   conducted	   in	   vitro	   experiments.	   Primary	   rat	   mesangial	   cells	   were	  cultured	  and	  stained	  for	  alpha-­‐smooth	  muscle	  actin	  and	  perlecan.	  Figure	  8A	  (left	  panel)	  shows	   a	   confocal	   image	   of	   cultured	   mesangial	   cells	   for	   alpha-­‐smooth	   muscle	   actin	  (activation	   marker	   of	   mesangial	   cells)	   and	   perlecan,	   thus	   showing	   that	   activated,	  proliferating	   mesangial	   cells	   express	   perlecan.	   Figure	   8A	   (right	   panel)	   shows	   a	  magnification	   of	   a	   Z-­‐stack	   compilation,	   and	   clearly	   demonstrates	   the	   extracellular	  presence	  of	  perlecan	  positioned	  on	  the	  cell	  membrane.	  We	  next	  compared	  resting	  (2%	  FCS	  culture	  conditions)	  with	  proliferating	  (10%	  FCS	  culture	  conditions)	  mesangial	  cells	  with	   respect	   to	   perlecan	   expression.	   Quantitative	   Tissue	   FAXS	   analysis	   showed	   a	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proliferative	  response	  when	  mesangial	  cells	  are	  cultured	  with	  10%	  FCS	  (Figure	  8B	  and	  C).	  The	  absolute	  number	  of	  perlecan	  positive	  mesangial	  cells	  increased	  under	  10%	  FCS	  conditions.	  The	  percentage	  of	  perlecan	  positive	  cells	  however	  decreased	  under	  10%	  FCS	  conditions.	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	   	  
Figure	  7.	  Glomerular	  and	  arterial	  expression	  of	  FGF2	  in	  allografts	  with	  CTD.	  Endogenous	  expression	  of	  FGF2	  was	  evaluated	  by	  immunofluorescence	  (A-­‐B)	  and	  qRT-­‐PCR	  (C-­‐D).	  In	  allografts	  with	  CTD,	  a	  strong	  expression	  of	  FGF2	  was	  exclusively	  found	  in	  glomeruli	  (A)	  and	  neointimae	  (B).	  In	  glomeruli	  of	  isografts	  a	  slight	  increase	  in	  FGF2	  expression	  was	  found	  (A).	  The	  dotted	  line	  represents	  the	  internal	  elastic	  lamina.	  C	  (left):	  Quantification	  of	  glomerular	  FGF2	  expression	  by	  digital	  image	  analysis	  showed	  significant	  increase	  in	  allografted	  kidneys.	  **	  p<0.01;	  ***	  p<0.001.	  qRT-­‐PCR	  analysis	  revealed	  an	  increase	  in	  FGF2	  expression	  in	  the	  glomeruli	  in	  allografts,	  which	  did	  however	  reach	  the	  level	  of	  statistical	  significance	  when	  compared	  with	  isografts	  and	  non-­‐transplanted	  control	  tissue	  	  (C,	  right).	  Neointimal	  expression	  of	  FGF2	  was	  clearly	  present	   (D)	   (n=5/group).	   Scale	   bars	   represent	   50	   µm	   as	   indicated	   in	   the	   Figure.	   Blank	   (PBS	   control)	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represents	  the	  staining	  without	  incubation	  by	  anti-­‐FGF2	  mAb,	  in	  the	  presence	  of	  DAPI	  to	  show	  the	  nuclei	  of	  renal	  allograft	  	  
	  
	  
Figure	  8.	  Proliferating	  mesangial	  cells	  express	  perlecan	  on	  their	  cell	  membranes.	  A:	  Proliferating	  rat	  mesangial	   cells	  were	   double-­‐stained	   for	   alpha-­‐smooth	  muscle	   actin	   and	   perlecan	   in	   order	   to	   show	  perlecan	  expression	  on	  the	  cell	  membranes	  of	  proliferating	  mesangial	  cells.	  Magnification	  in	  A	  (right)	  is	  a	  compressed	  confocal	  Z-­‐scan	  of	  2.63	  µm	  consisting	  of	  7	  stacks.	  B	  and	  C:	  resting	  (2%	  FCS)	  mesangial	  cell	  cultures	  were	   compared	  with	  proliferating	   (10%	  FCS)	   cultures	  with	   respect	   to	   cell	   numbers	   (based	  on	  DAPI	   staining)	   and	   perlecan	   expression	   (Alexa	   488).	   In	   B	   the	   Tissue	   FAXS	   scatter	   plots	   are	   shown.	  Quantification	  of	   the	  data	   is	  given	   in	  C.	  10%	  FCS	   induced	  significant	  proliferation	  of	   the	  mesangial	  cells	  (left),	   with	   rise	   in	   absolute	   number	   of	   perlecan-­‐positive	   mesangial	   cells	   (middle).	   Relatively,	   the	  percentage	  of	  perlecan-­‐positive	  cells	  was	  decreased	  after	  culturing	  with	  10%	  FCS	  compared	  to	  2%	  FCS.	  *	  p<0.05;	  **	  p<0.01	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To	  demonstrate	  proliferation	  of	  mesangial	  cells	  in	  allografted	  kidneys	  in	  vivo,	  a	  double	  staining	   was	   performed	   using	  mesangial	   cell	   marker	   (Thy-­‐1	   =	   CD90)	   with	   Ki67	   as	   a	  proliferation	  marker.	  In	  allografted	  kidneys	  the	  number	  of	  Ki67-­‐positive	  nuclei	  was	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  9.	  Proliferation	  of	  perlecan-­‐positive	  mesangial	  cells	  in	  allografted	  kidneys.	  A:	  Kidneys	  from	  non-­‐transplanted	  controls,	  isografted	  and	  allografted	  rats	  were	  stained	  for	  perlecan.	  Strong	  induction	  of	  perlecan	  is	  seen	  in	  the	  glomeruli	  of	  the	  allografts.	  B:	  in	  the	  same	  kidneys	  (as	  in	  panel	  A)	  a	  double	  staining	  was	  performed	  using	  OX7	  (Thy-­‐1	  =	  CD90)	  as	  rat	  mesangial	  phenotypic	  marker	  	  with	  Ki67	  as	  proliferation	  marker.	   	   These	   stainings	   revealed	   presence	   of	  Ki67-­‐positive	   nuclei	   (arrowheads)	   in	   the	  Thy-­‐1	   positive	  mesangial	   areas	  within	   the	  glomeruli	   of	   allografted	  kidneys,	  which	  was	  not	  observed	   in	   isografted	  and	  non-­‐transplant	  control	  kidneys.	  Arrows	  indicate	  Ki67-­‐positive	  proliferating	  interstitial	  cells. 	  increased	   in	   Thy-­‐1	   positive	   mesangial	   areas	   within	   the	   glomeruli,	   which	   was	   not	  observed	  in	  isografted	  and	  non-­‐transplant	  control	  kidneys	  (Figure	  9B).	  In	  Figure	  9A	  we	  show	  the	  perlecan	  expression	  in	  the	  same	  kidneys,	  thus	  demonstrating	  that	  mesangial	  proliferation	  associates	  with	  increased	  perlecan	  in	  the	  same	  allografts.	  Figure	   10A	   shows	   a	   dose-­‐dependent	   increase	   in	   proliferation	   of	   mesangial	   cells	   in	  response	  to	  FGF2.	  The	  FGF2-­‐induced	  proliferative	  response	  was	  blunted	  by	  the	  addition	  of	   exogenous	   competitive	   bovine	   kidney-­‐derived	   HS	   (Figure	   10B).	   This	   was	   due	   to	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reduced	  binding	  of	  FGF2	  to	  the	  cells	  as	  demonstrated	  by	  rudeces	  binding	  of	  125I-­‐labeled	  FGF2	   to	   the	  mesangial	   cells	   (not	   shown).	  To	   show	   that	  proliferation	  of	   the	  mesangial	  cells	   was	   dependent	   on	   FGF2	   binding	   by	   endogenous	   HS,	   cells	   were	   cultured	   in	   the	  presence	  of	  chlorate,	  which	  inhibited	  the	  sulfation	  of	  the	  side	  chains	  of	  the	  FGF2	  to	  the	  
	  	  	  	  	  	   	  
Figure	  10.	  FGF2-­‐induced	  proliferation	  of	  mesangial	  cells	  depends	  on	  sulfated	  proteoglycans.	  A:	  Rat	  primary	  mesangial	  cells	  were	  stimulated	  with	  various	  concentrations	  of	  FGF2	  for	  24	  h.	  Proliferation	  was	  measured	  by	  3H-­‐thymidine	  incorporation.	  Data	  are	  expressed	  as	  the	  stimulation	  index,	  i.e.	  fold	  increase	  in	  proliferation	  +	  FGF2	  /	  proliferation	  –	  FGF2	  (n=4;	  *p<0.05,	  **p<0.01	  vs.	  no	  FGF2	  added).	  B:	  Exogenous	  HS	  from	   bovine	   kidney	   (HSBK)	   hampers	   FGF2-­‐induced	   mesangial	   cell	   proliferation	   in	   a	   dose-­‐dependent	  manner	   (n=2).	  C:	   Proteoglycan	   sulfation	  of	  mesangial	   cells	   is	   reduced	  by	   chlorate	   in	   a	   dose-­‐dependent	  manner	  (**p<0.01,	  ***p<0.001	  vs.	  no	  chlorate	  added).	  D:	  Chlorate	  impairs	  FGF2-­‐induced	  proliferation	  of	  mesangial	  cells	  which	  is	  dependent	  on	  the	  duration	  of	  FGF2	  stimulation	  (***p<0.001	  vs.	  no	  chlorate	  at	  the	  respective	  duration	  of	  FGF2	  stimulation).	  	  mesangial	   cells	   (not	   shown).	   To	   show	   that	   proliferation	   of	   the	   mesangial	   cells	   was	  dependent	  on	  FGF2	  binding	  by	  endogenous	  HS,	  cells	  were	  cultured	   in	   the	  presence	  of	  chlorate,	  which	  inhibited	  the	  sulfation	  of	  the	  side	  chains	  of	  the	  proteoglycans	  in	  a	  dose-­‐dependent	   manner	   (Figure	   10C).	   Indeed,	   chlorate	   prevented	   the	   FGF2-­‐induced	  proliferative	   response	   of	   mesangial	   cells,	   which	   appeared	   to	   be	   dependent	   on	   the	  duration	  of	  FGF2	  stimulation	  (Figure	  10D).	  These	  results	  indicate	  that	  the	  proliferation	  of	  mesangial	  cells	  is	  dependent	  on	  FGF2	  binding	  to	  endogenous	  HS	  proteoglycans	  such	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as	   perlecan.	   The	   interaction	   between	   FGF2	   and	   HS	   proteoglycans	   on	   mesangial	   cells	  may	  therefore	  play	  a	  key	  role	  in	  the	  development	  of	  FGS.	  	  
DISCUSSION	  
	  In	   this	   study	   we	   provide	   evidence	   that	   matrix	   HSPGs	   such	   as	   perlecan	   serve	   as	  functional	  docking	  platforms	  for	  FGF2	  and	  contribute	  to	  glomerular	  and	  arterial	  tissue	  remodeling	   in	   experimental	   CTD.	   The	   concept	   of	   extracellular	   regulation	   of	   growth	  factors	  by	  proteoglycans	  has	  been	  studied	  predominantly	   in	  tissue	  remodeling	  related	  to	  embryonic	  development	  (14,15),	  ontogenesis	  (16,17)	  and	  angiogenesis	  (18,19).	  Our	  data	  indicate	  that	  HSPGs	  modulate	  growth	  factors	  in	  the	  renal	  transplant	  setting	  as	  well.	  This	   is	   an	   important	   finding	   that	   opens	   the	   possibility	   to	   target	   proteoglycans	   by	  therapeutic	  intervention	  to	  ameliorate	  the	  development	  of	  CTD.	  Development	   of	   CTD	   in	   renal	   allografts	   is	   the	   result	   of	   tissue	   remodeling	   affecting	   all	  functional-­‐structural	   compartments	   of	   the	   kidney	   including	   the	   tubulointerstitium	  (tubular	   atrophy	   and	   interstitial	   fibrosis),	   glomeruli	   (focal	   glomerulosclerosis),	   and	  larger	  arteries	  (neointima	  formation)	  (2-­‐4).	  We	  previously	  demonstrated	  compositional	  changes	  of	  the	  HSPGs	  collXVIII,	  perlecan	  and	  agrin	  in	  tissue	  remodeling	  in	  experimental	  CTD	   by	   immunofluorescence	   (5).	   We	   now	   investigated	   functional	   aspects	   of	  proteoglycans	  in	  experimental	  CTD	  as	  well	  as	  in	  renal	  cell	  culture	  assays.	  Depending	  on	  their	   highly	   variable	   composition,	   HS	   carbohydrate	   side	   chains	   can	   bind	   a	   variety	   of	  ligands	  including	  FGF2	  (12),	  which	  is	  known	  to	  be	  involved	  in	  renal	  tissue	  remodeling.	  In	   experimental	   allografts	   with	   CTD,	   a	   massive	   increase	   in	   matrix	   HSPG-­‐mediated	  binding	   capacity	   for	   FGF2	   was	   observed.	   Enhanced	   binding	   capacity	   for	   this	   growth	  factor	   was	   the	   result	   of	   increased	   HSPG	   expression,	   and	   modified	   HS	   sulfation.	   Data	  indicate	   increased	   N-­‐	   and	   2-­‐O	   sulfation	   leading	   to	   loss	   of	   JM-­‐403	   staining	   (28)	   and	  increased	  FGF2	  binding	   (32),	  however	  without	  an	   increase	   in	  6-­‐O	   sulfation,	   since	  6-­‐O	  sulfate	  dependent	  L-­‐selectin	  binding	  (45)	  was	  not	  induced	  in	  glomerular	  and	  neointimal	  HS.	   This	   finding	   suggests	   that	   upon	   allo-­‐transplantation	   the	   kidney	   mobilizes	   matrix	  HSPGs	  to	  become	  docking	  molecules	  for	  heparin-­‐binding	  growth	  factors	  such	  as	  FGF2.	  This	  was	  also	  reported	  by	  Morita	  et	  al.	  (33)	  showing	  increased	  FGF2	  binding	  in	  fibrotic	  areas	  of	  native	  kidney	  diseases.	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The	   laser	   microdissection	   approach	   on	   isolated	   glomeruli,	   arterial	   mediae	   and	  neointimae	  revealed	  spatial	  differences	   in	  HSPG	  expression,	  which	  were	  not	  seen,	  and	  would	   have	   been	   missed,	   in	   whole	   kidney	   homogenates.	   We	   observed	   increased	  glomerular	   and	   neointimal	   perlecan	   expression	   in	   allografted	   kidneys.	   This	   regional	  HSPG	  regulation	  opposes	  the	  uniform	  induction	  of	  pro-­‐fibrotic	  pathways	  (Coll	  I,	  Coll	  IV,	  TGF-­‐β1)	  seen	   in	  glomeruli,	  mediae	  and	  whole	  kidney	  tissue,	  which	  probably	  reflects	  a	  more	   generalized	   response	   upon	   allo-­‐transplantation.	   Like	   perlecan,	   FGF2	   showed	   a	  restricted	  glomerular	  and	  neointimal	  expression	  pattern	  as	  well.	  These	  findings	  indicate	  that	  the	  perlecan-­‐FGF2	  axis	  is	  not	  relevant	  for	  the	  interstitial	  fibrosis	  seen	  in	  the	  same	  rat	  CTD	  model.	  Apparently,	  tubulo-­‐interstitial	  fibrosis	  is	  driven	  by	  other	  (proteoglycan-­‐independent)	  growth	  factors	  such	  as	  TGF-­‐β.	  The	  marked	  FGF2	  and	  perlecan	  expression	  observed	   in	   glomeruli	   of	   allografted	   kidneys	   suggests	   a	   role	   in	   the	   proliferative	  response	  of	  mesangial	   cells,	  which	  was	  substantiated	  by	  showing	  Ki67-­‐positive	  nuclei	  within	   Thy-­‐1	   positive	   mesangial	   cells	   in	   allografted	   kidneys.	   In	   other	   settings	  perlecan/FGF2	   has	   been	   shown	   to	   induce	   proliferation	   in	   a	   number	   of	   cell	   types	  including	  chondrocytes,	  neural	  stem	  cells,	  retinal	  pigmental	  epithelial	  cells	  and	  vascular	  smooth	  muscle	  cells	  (19,34-­‐36).	  In	  the	  kidney	  FGF2	  has	  been	  shown	  to	  be	  proliferative	  for	  fibroblasts	  and	  mesangial	  cells	  (37,38).	  In	  vitro	  studies	  showed	  that	  the	  expression	  of	   cell	   surface	   HSPG	   was	   a	   prerequisite	   for	   the	   proliferation	   of	   renal	   fibroblasts	   in	  response	   to	   FGF2	   (37).	   We	   therefore	   studied	   the	   functional	   role	   of	   the	   FGF2-­‐proteoglycan	   interaction	   in	   mesangial	   cell	   proliferation	   in	   vitro.	   FGF2	   was	   shown	   to	  induce	  mesangial	   cell	  proliferation	   in	  a	  dose-­‐	  and	  sulfation-­‐dependent	  manner	   indeed	  favoring	  for	  a	  role	  of	  the	  FGF2-­‐proteoglycan	  interaction	  in	  mesangial	  cell	  proliferation.	  The	   exact	   mechanism	   by	   which	   HSPGs	   enhance	   FGF2-­‐induced	   mesangial	   cell	  proliferation	   is	   unknown.	   We	   propose	   that	   binding	   of	   FGF2	   to	   mesangial	   (matrix)	  HSPGs	   such	   as	   perlecan	   facilitates	   the	   interaction	   between	   FGF2	   and	   its	   surface	  receptor	  on	  mesangial	  cells,	  as	  has	  been	  demonstrated	  for	  other	  cell	  types	  (34-­‐39).	  This	  is	   supported	   by	   our	   observation	   that	   removing	   the	   FGF2	   binding	   capacity	   of	  proteoglycans	  on	  mesangial	  cells	  by	  chlorate	   treatment	  resulted	   in	  a	  significant	  delay,	  but	   not	   complete	   abrogation	   of	   FGF2-­‐induced	   proliferation.	   In	   a	   separate	   series	   of	  experiments	  we	  excluded	  a	  direct	  effect	  of	  perlecan	  on	  a	  fibrogenic	  response	  (qRT-­‐PCR	  for	  TGF-­‐β,	  Col	  IαI,	  Col	  IVαI)	  by	  the	  mesangial	  cells	  (results	  not	  shown).	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Based	   on	   our	   data,	   HSPGs	   could	   be	   interesting	   therapeutic	   targets	   to	   limit	   CTD,	  especially	   focusing	  on	   the	  potential	  of	   inhibiting	  growth	   factor	  signaling.	  To	  study	   the	  possibility	   that	   exogenous	   glycosaminoglycans	  may	   hamper	   growth	   factor	   responses,	  heparin(oids)	   have	   been	   shown	   to	   reduce	   progressive	   renal	   failure	   in	   experimental	  renal	  diseases,	   including	   renal	   transplantation	  (40-­‐42).	   Increasing	   research	   interest	   is	  focusing	  on	  the	  possibility	  to	  produce	  small	  HS-­‐mimetics,	  which	  may	  more	  specifically	  target	   a	   particular	   component	   of	   HS/heparin	   bioactivity	   (43).	   The	   use	   of	   HSPGs	   as	  targets,	   for	   example	   using	   antibodies	   that	   recognize	   and	   thereby	   block	   specific	   HS-­‐motifs/domains,	  may	  also	  have	  clinical	  potential.	  This	  strategy	  has	  been	  exemplified	  in	  
vitro	   by	   the	   demonstration	   that	   6-­‐O-­‐sulfate	   specific	   anti-­‐HS	   antibodies	   produced	   in	   a	  phage-­‐display	   library	   can	   inhibit	   leukocyte	   rolling	   and	   firm	   adhesion	   to	   glomerular	  endothelial	   cells,	   whereas	   anti-­‐HS	   antibodies	   with	   different	   specificities	   do	   not	   (44).	  Mutant	  growth	  factors,	  which	  are	  made	  incapable	  of	  glycosaminoglycan	  binding,	  could	  be	   used	   to	   specifically	   inhibit	   cell	   survival/proliferation.	   In	   addition,	   small	   inactive	  growth	  factor	  fragments	  could	  be	  generated	  that	  block	  the	  HSPG-­‐binding	  sites	  of	  their	  in	  
vivo	   active	   counterparts.	   Together,	   there	   are	   various	   options	   for	   the	   use	   of	   HSPGs	   in	  therapeutic	  strategies,	  but	  further	  proof	  of	  efficacy	  in	  vivo	  needs	  to	  be	  provided. 
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Supplemental	  Figure	  1.	  	  Proteoglycan	  mRNA	  expression	  profiles	  in	  microdissected	  glomeruli	  (left	  
column),	   arteries	   (middle	   column)	   and	   total	   kidney	   lysates	   (right	   column)	   of	   non-­‐transplanted	  
control	  tissue,	  isografts	  and	  allografts	  with	  CTD.	  Expression	  of	  syndecan-­‐1	  (A),	  syndecan-­‐4	  (B),	  agrin	  (C),	  biglycan	  (D)	  and	  versican	  (E)	  was	  analyzed	  using	  qRT-­‐PCR	  (glomeruli	  and	  arteries:	  n=5/group;	  whole	  kidney,	  n=3/group).	  Transcripts	  for	  the	  various	  proteoglycans	  were	  expressed	  as	  fold	  change	  compared	  to	  non-­‐transplanted	  control	  tissue	  samples.	  *	  p<0.05;	  **	  p<0.01	  
	  
	  
	  
  
	  
